Allosteric modulators of dopamine D2 receptors have untapped clinical potential as more efficient and safer drugs for a number of central nervous system (CNS) disorders, including schizophrenia and Parkinson’s disease (PD). The gene discussed is DRD2; the disease is schizophrenia.